Related Experiment Videos
[Phosphodiesterase inhibitors]
Annales De Cardiologie Et D'Angeiologie
|September 1, 1990
Insights
Phosphodiesterase III inhibitors offer a new treatment for congestive cardiac failure by increasing intracellular calcium. While they improve hemodynamics and oxygen consumption, long-term survival benefits remain unknown.
Area of Science:
- Pharmacology
- Cardiology
- Biochemistry
Abstract:
Phosphodiesterase III inhibitors constitute a new therapeutic group for congestive cardiac failure. They inhibit the degradation of cyclic adenosine monophosphate and increase the intracellular calcium. They have a double inotropic and vasodilator haemodynamics occurs without any increase in the myocardial effect. The improvement in the consumption of oxygen. The beneficial haemodynamic effect seems to last over a medium period of time, but the survival in the long term treatment is not yet known.